The type 2 diabetes drug rosiglitazone (Avandia) may have the ability to improve memory in people with Alzheimer's disease, a new US study has revealed.
Researchers at the University of Texas Medical Branch tested the controversial medicine, which was banned in Europe in 2010 due to heart health concerns, on a group of genetically modified mice designed to serve as models for Alzheimer's.
They and found that it had a positive effect on their cognitive performance, enhancing both learning and memory by targeting a key brain-signalling molecule known as ERK (extracellular signal-regulated kinase).
ERK becomes hyperactive both in the brains of Alzheimers patients and in the mice at a disease stage corresponding to mild cognitive impairment in human Alzheimer's, the scientists explained. This excessive activity leads to improper synaptic transmission between neurons, affecting memory and learning ability.
Rosiglitazone stabilises ERK's activity by triggering the peroxisome proliferator-activated receptor gamma (PPAR') pathway, which interacts with genes that respond to both PPAR' and ERK.
UTMB professor Larry Denner, the lead author of the study, said: "Using this drug appears to restore the neuronal signalling required for proper cognitive function.
"It gives us an opportunity to test several FDA-approved drugs to normalize insulin resistance in Alzheimer's patients and possibly also enhance memory, and it also gives us a remarkable tool to use in animal models to understand the molecular mechanisms that underlie cognitive issues in Alzheimer's."
The findings appear in the latest issue of the Journal of Neuroscience.
Diabetes drug a memory booster for Alzheimers patients
Fri, 23 Nov 2012
Your comments may be moderated. Please report any spam, illegal, offensive or libellous posts.
Also related to this storyAlzheimers and diabetes
Diabetes guides and information
Newly diagnosed with diabetes
What is pre-diabetes
Blood sugar level ranges
Guide to blood glucose testing
Diabetic food, diet and recipes
Diabetes and pregnancy
Diabetes travel guide
Free diabetic travel insurance quote
Online diabetes shop
Join the diabetes newsletter
Diabetes clinical trials
Continuous glucose monitoring
Positive trial results for once-weekly diabetes drug dulaglutide
Huge growth in sales forecast for type 2 diabetes drugs
Drug offers new approach for type 2 diabetes treatment
Diabetes drug may have potential to treat Alzheimers
Zealand Pharma begins clinical development of type 2 diabetes drug
Clopidogrel drug may be less beneficial for diabetic patients after MI
Overdose drug shows heart potential for type 2 diabetes patients
FDA approves generic versions of diabetes drug Actos
Use of Tradjenta diabetes drug expended in the US
More than 40m diabetes drugs prescribed in 2011/12
Type 2 diabetes drugs raise bladder cancer risk
Diabetes drugs deliver strong results for Novo Nordisk
Jentadueto combination diabetes drug gets European approval
Lucentis drug can treat diabetes-related vision loss
Aurobindo diabetes drug approved by US health regulator
Janssen to assist development of regenerative diabetes drugs
Metformin diabetes drug could mend injured brains
Diabetes drug Actos associated with bladder cancer once more
Antipsychotic drug use ups risk of gestational diabetes
GSK fined GBP1.9bn for illegal off-label marketing of drugs
EMA updates guidelines for diabetes drugmakers
Bristol-Myers and AstraZeneca team up to buy rival drug maker Amylin